Indivior Pharmaceuticals, Inc. balance sheet SUPN

Annual Quarterly

As of Sep 30, 2026, Indivior Pharmaceuticals, Inc. had total assets of $1.3 billion and total liabilities of $1.4 billion. Total assets were down 5.9% from a year earlier. Stockholders' equity was negative, at -$60.0 million, because liabilities exceed assets. It held $332.0 million in cash and investments against $501.0 million of total debt, net debt of $169.0 million. The current ratio, current assets divided by current liabilities, was 0.61.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Assets
Cash	305 -31.5%	222 -56.5%	175 -53.0%	195 -38.9%	445	510	372	319 +0.9%
Short-term investments	—	—	—	0 -100.0%	0	0	1	1
Long-term investments	27 -3.6%	27 +0.0%	27 +0.0%	28 +3.7%	28	27	27	27
Cash and investments	332 -29.8%	249 -53.6%	202 -49.5%	223 -35.7%	473	537	400	347 +9.8%
Receivables	273 +5.4%	271 +12.9%	273 +12.3%	253 -0.4%	259	240	243	254
Inventory	149 -3.9%	150 +0.7%	152 -6.7%	153 -8.4%	155	149	163	167
Total current assets	800 -13.2%	725 -23.8%	667 -24.5%	652 -21.2%	922	951	883	827
Property and equipment, net	175 +41.1%	162 +38.5%	157 +51.0%	144 +44.0%	124	117	104	100
Goodwill	—	—	—	2 +0.0%	—	—	—	2
Total assets	1,332 -5.9%	1,233 -15.1%	1,197 -12.9%	1,201 -8.7%	1,416	1,452	1,375	1,316 -25.1%
Liabilities and equity
Accounts payable	28 -31.7%	30 -40.0%	35 -23.9%	48 -23.8%	41	50	46	63
Total current liabilities	1,301 +34.8%	868 -17.8%	779 -22.5%	914 -1.1%	965	1,056	1,005	924
Total liabilities	1,392 -14.2%	1,441 -15.7%	1,341 -19.2%	1,300 -21.3%	1,623	1,709	1,660	1,652 -14.9%
Stockholders' equity	-60 +71.0%	-208 +19.1%	-144 +49.5%	-98 +70.9%	-207	-257	-285	-337
Debt
Debt due within a year	488 +2611.1%	—	—	29 +61.1%	18	18	18	18 -94.3%
Long-term debt	0 -100.0%	487 +58.1%	486 +56.3%	290 -7.9%	304	308	311	315
Lease liabilities	13 -61.8%	22 -45.0%	23 -43.9%	32 -23.8%	34	40	41	42 -2.3%
Total debt	501 +40.7%	509 +39.1%	509 +37.6%	351 -6.4%	356	366	370	375 +5.0%
Net cash	-169 -244.4%	-260 -252.0%	-307 -1123.3%	-128 -357.1%	117	171	30	-28 +31.7%
Ratios
Current ratio	0.61x	0.84x	0.86x	0.71x	0.96x	0.90x	0.88x	0.90x
Debt to EBITDA	0.89x	1.18x	1.49x	1.29x	—	—	—	6.94x
Return on assets	33.78%	28.87%	21.05%	17.49%	—	—	—	0.53%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: INDV (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Rockville, MD
SEC filer status: Large accelerated filer
SEC CIK: 1625297
Former names: Indivior Pharmaceuticals, Inc. (until Nov 2, 2026); INDIVIOR PLC (until Jan 8, 2026)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.